It is a binding partner of Gal-1 and Gal-3, which promote integrin-mediated cell adhesion, and significantly elevated expression of Gal-3 BP in the serum or tumor tissues is associated with poor prognosis in a variety of malignancies including breast cancer (29), lung cancer (30), and PC (31). Here, LGALS1 is linked to breast cancer.